Tourmaline Bio Files Q1 2025 10-Q
| Field | Detail |
|---|---|
| Company | Tourmaline Bio, Inc. |
| Form Type | 10-Q |
| Filed Date | May 2, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, biotech, financials
TL;DR
Tourmaline Bio dropped its Q1 2025 10-Q. Check financials.
AI Summary
Tourmaline Bio, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial results and provided updates on its business operations. Key financial figures and operational details for the first quarter of 2025 are included in the filing.
Why It Matters
This filing provides investors with the latest financial performance and operational status of Tourmaline Bio, crucial for understanding the company's trajectory in the biotechnology sector.
Risk Assessment
Risk Level: medium — As a biotechnology company, Tourmaline Bio faces inherent risks related to drug development, clinical trials, and regulatory approvals.
Key Players & Entities
- Tourmaline Bio, Inc. (company) — Filer of the 10-Q
- Talaris Therapeutics, Inc. (company) — Former company name
- 20250331 (date) — Period of report
- 20250502 (date) — Filing date
FAQ
What was Tourmaline Bio's former company name?
Tourmaline Bio, Inc.'s former company name was Talaris Therapeutics, Inc.
What is the fiscal year end for Tourmaline Bio?
Tourmaline Bio's fiscal year ends on December 31.
What is the SEC file number for Tourmaline Bio?
The SEC file number for Tourmaline Bio is 001-40384.
What is the business address of Tourmaline Bio?
The business address of Tourmaline Bio is 27 WEST 24TH STREET, SUITE 702, NEW YORK, NY 10010.
What is the SIC code for Tourmaline Bio?
The Standard Industrial Classification (SIC) code for Tourmaline Bio is 2836, for Biological Products (No Diagnostic Substances).
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 2, 2025 regarding Tourmaline Bio, Inc..